Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity.
Publication
, Journal Article
Nakajima, H; Cella, M; Bouchon, A; Grierson, HL; Lewis, J; Duckett, CS; Cohen, JI; Colonna, M
Published in: Eur J Immunol
November 2000
Patients with the X-linked lymphoproliferative disorder (XLPD) are unable to control Epstein-Barr virus (EBV)-induced infections and lymphoproliferation. This disease is caused by a deficit of SAP, an adapter protein involved in the signal transduction of several cell surface receptors of the CD2 superfamily. One of these receptors, called 2B4, is expressed on NK cells, cytotoxic T cells and myeloid cells and activates NK cell cytotoxicity. Here we show that XLPD patients have a defect of 2B4 receptor-mediated NK cell cytotoxicity. This defect may contribute to the pathogenesis of XLPD by reducing NK cell lysis of EBV-infected B cells.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Eur J Immunol
DOI
ISSN
0014-2980
Publication Date
November 2000
Volume
30
Issue
11
Start / End Page
3309 / 3318
Location
Germany
Related Subject Headings
- Signaling Lymphocytic Activation Molecule Family
- Signaling Lymphocytic Activation Molecule Associated Protein
- Signal Transduction
- Receptors, Immunologic
- Membrane Glycoproteins
- Lymphoproliferative Disorders
- Killer Cells, Natural
- Intracellular Signaling Peptides and Proteins
- Immunology
- Humans
Citation
APA
Chicago
ICMJE
MLA
NLM
Nakajima, H., Cella, M., Bouchon, A., Grierson, H. L., Lewis, J., Duckett, C. S., … Colonna, M. (2000). Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. Eur J Immunol, 30(11), 3309–3318. https://doi.org/10.1002/1521-4141(200011)30:11<3309::AID-IMMU3309>3.0.CO;2-3
Nakajima, H., M. Cella, A. Bouchon, H. L. Grierson, J. Lewis, C. S. Duckett, J. I. Cohen, and M. Colonna. “Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity.” Eur J Immunol 30, no. 11 (November 2000): 3309–18. https://doi.org/10.1002/1521-4141(200011)30:11<3309::AID-IMMU3309>3.0.CO;2-3.
Nakajima H, Cella M, Bouchon A, Grierson HL, Lewis J, Duckett CS, et al. Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. Eur J Immunol. 2000 Nov;30(11):3309–18.
Nakajima, H., et al. “Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity.” Eur J Immunol, vol. 30, no. 11, Nov. 2000, pp. 3309–18. Pubmed, doi:10.1002/1521-4141(200011)30:11<3309::AID-IMMU3309>3.0.CO;2-3.
Nakajima H, Cella M, Bouchon A, Grierson HL, Lewis J, Duckett CS, Cohen JI, Colonna M. Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. Eur J Immunol. 2000 Nov;30(11):3309–3318.
Published In
Eur J Immunol
DOI
ISSN
0014-2980
Publication Date
November 2000
Volume
30
Issue
11
Start / End Page
3309 / 3318
Location
Germany
Related Subject Headings
- Signaling Lymphocytic Activation Molecule Family
- Signaling Lymphocytic Activation Molecule Associated Protein
- Signal Transduction
- Receptors, Immunologic
- Membrane Glycoproteins
- Lymphoproliferative Disorders
- Killer Cells, Natural
- Intracellular Signaling Peptides and Proteins
- Immunology
- Humans